Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 46 | 2025 | 401 | 16.790 |
Why?
|
| Stroke Volume | 21 | 2025 | 104 | 4.400 |
Why?
|
| Cardiovascular Diseases | 9 | 2025 | 532 | 3.540 |
Why?
|
| Influenza Vaccines | 6 | 2025 | 292 | 2.800 |
Why?
|
| Pandemics | 9 | 2022 | 287 | 2.640 |
Why?
|
| Hospitalization | 15 | 2024 | 804 | 2.550 |
Why?
|
| Humans | 65 | 2025 | 17314 | 2.540 |
Why?
|
| Influenza, Human | 6 | 2025 | 282 | 2.450 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2022 | 53 | 1.940 |
Why?
|
| Cardiology | 3 | 2022 | 28 | 1.600 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 50 | 1.580 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 57 | 1.570 |
Why?
|
| Treatment Outcome | 14 | 2025 | 1160 | 1.520 |
Why?
|
| Vaccination | 6 | 2025 | 688 | 1.410 |
Why?
|
| Biphenyl Compounds | 7 | 2022 | 10 | 1.280 |
Why?
|
| Aminobutyrates | 7 | 2022 | 18 | 1.270 |
Why?
|
| Aged | 19 | 2025 | 6084 | 1.210 |
Why?
|
| Drug Combinations | 7 | 2022 | 43 | 1.130 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 224 | 1.120 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2022 | 19 | 1.100 |
Why?
|
| Valsartan | 6 | 2022 | 11 | 1.080 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 68 | 1.070 |
Why?
|
| Patient Care Team | 2 | 2024 | 105 | 1.050 |
Why?
|
| Neprilysin | 4 | 2022 | 10 | 0.930 |
Why?
|
| Male | 20 | 2025 | 9804 | 0.920 |
Why?
|
| Text Messaging | 1 | 2025 | 34 | 0.910 |
Why?
|
| Betacoronavirus | 3 | 2020 | 37 | 0.870 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 17 | 0.860 |
Why?
|
| Middle Aged | 14 | 2025 | 7836 | 0.830 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 310 | 0.810 |
Why?
|
| Hospital Mortality | 7 | 2022 | 131 | 0.800 |
Why?
|
| Registries | 6 | 2023 | 460 | 0.790 |
Why?
|
| Cardiovascular System | 1 | 2022 | 3 | 0.780 |
Why?
|
| Curriculum | 1 | 2022 | 36 | 0.770 |
Why?
|
| Female | 18 | 2025 | 12396 | 0.760 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2022 | 7 | 0.760 |
Why?
|
| Heart Diseases | 2 | 2021 | 71 | 0.750 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 44 | 0.750 |
Why?
|
| United States | 11 | 2025 | 3866 | 0.740 |
Why?
|
| Tetrazoles | 4 | 2022 | 15 | 0.730 |
Why?
|
| Eye Diseases | 1 | 2021 | 6 | 0.720 |
Why?
|
| Medicine | 1 | 2021 | 18 | 0.720 |
Why?
|
| Enalapril | 1 | 2021 | 8 | 0.720 |
Why?
|
| Polypharmacy | 1 | 2021 | 13 | 0.720 |
Why?
|
| Patient Discharge | 2 | 2021 | 153 | 0.720 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 86 | 0.690 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 44 | 0.680 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2018 | 13 | 0.670 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 169 | 0.590 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 6 | 0.550 |
Why?
|
| Heart Rate | 1 | 2017 | 38 | 0.530 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 53 | 0.530 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2022 | 84 | 0.520 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 1 | 0.520 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 51 | 0.510 |
Why?
|
| Buprenorphine | 1 | 2016 | 48 | 0.490 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 120 | 0.480 |
Why?
|
| Time Management | 1 | 2014 | 1 | 0.460 |
Why?
|
| Operating Rooms | 1 | 2014 | 2 | 0.460 |
Why?
|
| Clinical Medicine | 1 | 2014 | 4 | 0.440 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 1925 | 0.440 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 24 | 0.440 |
Why?
|
| Shock, Cardiogenic | 3 | 2022 | 6 | 0.420 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 173 | 0.410 |
Why?
|
| Renin-Angiotensin System | 3 | 2022 | 16 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 664 | 0.400 |
Why?
|
| Guideline Adherence | 3 | 2025 | 149 | 0.390 |
Why?
|
| Angiotensins | 2 | 2022 | 3 | 0.360 |
Why?
|
| Medicare | 2 | 2022 | 192 | 0.350 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 28 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2025 | 2415 | 0.350 |
Why?
|
| Aftercare | 2 | 2021 | 47 | 0.330 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 1151 | 0.330 |
Why?
|
| Peptide Fragments | 2 | 2021 | 28 | 0.310 |
Why?
|
| California | 2 | 2025 | 2311 | 0.300 |
Why?
|
| Outpatients | 2 | 2020 | 101 | 0.290 |
Why?
|
| Comorbidity | 2 | 2021 | 560 | 0.290 |
Why?
|
| Chronic Disease | 2 | 2022 | 397 | 0.280 |
Why?
|
| Cohort Studies | 2 | 2022 | 2514 | 0.250 |
Why?
|
| Prospective Studies | 4 | 2021 | 1226 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2021 | 142 | 0.230 |
Why?
|
| American Heart Association | 2 | 2022 | 48 | 0.230 |
Why?
|
| Troponin T | 2 | 2021 | 11 | 0.230 |
Why?
|
| Troponin | 2 | 2022 | 11 | 0.220 |
Why?
|
| Critical Care | 2 | 2022 | 66 | 0.220 |
Why?
|
| Cause of Death | 3 | 2019 | 176 | 0.210 |
Why?
|
| Risk Factors | 3 | 2021 | 3258 | 0.210 |
Why?
|
| Time Factors | 4 | 2021 | 1039 | 0.200 |
Why?
|
| Cardiotonic Agents | 2 | 2020 | 12 | 0.200 |
Why?
|
| Myeloproliferative Disorders | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 6 | 0.200 |
Why?
|
| Leukemia | 1 | 2022 | 9 | 0.200 |
Why?
|
| Adult | 4 | 2025 | 7500 | 0.190 |
Why?
|
| Acute Disease | 2 | 2020 | 144 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2021 | 1 | 0.190 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 3 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 312 | 0.190 |
Why?
|
| Drug Labeling | 1 | 2021 | 12 | 0.190 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 32 | 0.190 |
Why?
|
| Myocardium | 1 | 2021 | 6 | 0.180 |
Why?
|
| Health Care Costs | 2 | 2021 | 207 | 0.180 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 8 | 0.180 |
Why?
|
| Troponin I | 1 | 2021 | 8 | 0.180 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 11 | 0.180 |
Why?
|
| Patients | 1 | 2021 | 29 | 0.180 |
Why?
|
| Societies, Medical | 1 | 2021 | 71 | 0.180 |
Why?
|
| Information Dissemination | 1 | 2021 | 50 | 0.180 |
Why?
|
| Sympathetic Nervous System | 1 | 2020 | 3 | 0.170 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 1 | 0.170 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 11 | 0.170 |
Why?
|
| Research Design | 1 | 2023 | 336 | 0.170 |
Why?
|
| Heart Murmurs | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 1 | 0.170 |
Why?
|
| Triage | 1 | 2020 | 19 | 0.170 |
Why?
|
| Pneumonia | 1 | 2021 | 49 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 250 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 298 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 5 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2021 | 211 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 120 | 0.170 |
Why?
|
| Hospitals | 1 | 2020 | 71 | 0.170 |
Why?
|
| Disease Progression | 2 | 2021 | 259 | 0.170 |
Why?
|
| Fever | 1 | 2020 | 54 | 0.160 |
Why?
|
| Hemodilution | 1 | 2019 | 1 | 0.160 |
Why?
|
| Benzazepines | 1 | 2019 | 24 | 0.160 |
Why?
|
| Sitagliptin Phosphate | 1 | 2019 | 1 | 0.160 |
Why?
|
| Asia | 1 | 2019 | 12 | 0.160 |
Why?
|
| Diuretics | 1 | 2019 | 19 | 0.160 |
Why?
|
| North America | 1 | 2019 | 44 | 0.160 |
Why?
|
| Europe | 1 | 2019 | 46 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2020 | 92 | 0.160 |
Why?
|
| Length of Stay | 1 | 2020 | 171 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 123 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2020 | 225 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2021 | 235 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 437 | 0.140 |
Why?
|
| Digoxin | 1 | 2018 | 12 | 0.140 |
Why?
|
| Quality of Life | 2 | 2022 | 499 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2017 | 7 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 2 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 701 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2018 | 72 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 384 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2021 | 1076 | 0.130 |
Why?
|
| Administration, Sublingual | 1 | 2016 | 1 | 0.130 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 4 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 14 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 45 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 26 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 226 | 0.120 |
Why?
|
| Biomarkers | 3 | 2022 | 307 | 0.120 |
Why?
|
| Systems Analysis | 1 | 2014 | 4 | 0.110 |
Why?
|
| Time and Motion Studies | 1 | 2014 | 3 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2014 | 26 | 0.110 |
Why?
|
| Exercise | 1 | 2018 | 515 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2014 | 188 | 0.100 |
Why?
|
| Survival Rate | 2 | 2021 | 252 | 0.070 |
Why?
|
| Health Status | 2 | 2022 | 293 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 1266 | 0.070 |
Why?
|
| Prognosis | 2 | 2021 | 603 | 0.070 |
Why?
|
| Denmark | 1 | 2023 | 17 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2023 | 10 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2021 | 7 | 0.040 |
Why?
|
| Critical Illness | 1 | 2022 | 51 | 0.040 |
Why?
|
| Natriuretic Peptides | 1 | 2021 | 5 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 99 | 0.040 |
Why?
|
| Colchicine | 1 | 2020 | 1 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 10 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 6 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 22 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 3 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2020 | 56 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 44 | 0.040 |
Why?
|
| Decision Making | 1 | 2022 | 171 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 55 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 114 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 342 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 357 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 119 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 304 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 165 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 605 | 0.040 |
Why?
|
| France | 1 | 2018 | 11 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 70 | 0.040 |
Why?
|
| Systole | 1 | 2017 | 22 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2465 | 0.030 |
Why?
|
Concepts
(187)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->